News

NEWS

LATEST NEWS

Hemophilia: What Your Patients Need to Know

Does the failure of pembrolizumab in multiple myeloma clinical trials imply checkpoint inhibition is

Daratumumab Not Cost-Effective for Multiple Myeloma

$A pooled analysis of 3 combination drug regimens used to treat refractory/relapsed multiple myeloma$

Ixazomib in an Oral Triplet Therapy Shows Benefit for Newly Diagnosed Multiple Myeloma

Abecma Approved for Relapsed/Refractory Multiple Myeloma

Zoledronic acid effective for multiple myeloma

Can Premedications, Infusion Rates Be Adjusted Safely With Daratumumab for Multiple Myeloma?

An illustration of a thrombosis forming.

Rivaroxaban May Be Clinically Superior to LMWH in Patients With Cancer-Associated Thrombosis

Could myeloma-associated antibodies could one day serve as biomarkers for predicting which patients will benefit from isatuximab?

SIRT1 Inhibitor Cambinol Has Antitumor Activity in Multiple Myeloma Cells

UPCOMING MEETINGS

December 5 – 8, 2020
62ND ASH ANNUAL MEETING AND EXPOSITION
San Diego Convention Center, San Diego, CA

Click here to view the full calendar

DRUG NEWS FROM MPR

Pepaxto Approved for Triple-Class Refractory Multiple Myeloma

First CAR T-Cell Therapy Approved for Indolent Follicular Lymphoma

NIH: COVID-19 Convalescent Plasma Unlikely to Benefit ED Patients With Mild Symptoms

Vazalore, a Liquid-Filled Capsule Formulation of Aspirin, Gets FDA Approval

IV Iron Products: Adverse Events, Associated Costs Compared

FDA: More Data on Remestemcel-L for Graft-vs-Host Disease Needed

FDA Requires Boxed Warning Update for Benzodiazepines

FDA Approves New Treatment Option for Multiple Myeloma

Priority Review Granted to Tazemetostat for Follicular Lymphoma Indication

Esperoct Now Available for Treatment of Hemophilia A

Next post in News

NIH: COVID-19 Convalescent Plasma Unlikely to Benefit ED Patients With Mild Symptoms